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Abstract: BACKGROUND: Recently, it has been suggested that the type of stent used in primary
percutaneous coronary interventions (pPCI) might impact on outcomes of patients with acute myocardial
infarction (AMI). Indeed, drug-eluting stents (DES) reduce neointimal hyperplasia when compared to
bare-metal stents (BMS); moreover the later generation DES due to its biocompatible polymer coatings
and stent design allow for greater deliverability, improved endothelial healing and therefore less restenosis
rate and thrombus generation. However, data on the safety and performance of DES in large cohorts of
AMI are still limited. AIM: To compare the early outcome of DES vs. BMS in acute myocardial infarction
patients. METHODS: This was a prospective, multicenter analysis containing patients from 64 hospitals
in Switzerland with AMI undergoing pPCI between 2005 and 2013. The primary endpoint was in-hospital
all-cause death, whereas the secondary endpoint included a composite measure of major adverse cardiac
and cerebrovascular events (MACCE) of death, reinfarction, and cerebrovascular event. RESULTS: Of
20 464 patients with the primary diagnosis of AMI and enrolled to the AMIS Plus Registry, 15 026 were
referred for pPCI and 13 442 received stent implantation. 10 094 patients were implanted with DES
and 2 260 with BMS. The overall in-hospital mortality was significantly lower in patients with DES as
compared to those with BMS implantation (2.6% vs. 7.1%, p<0.001). The overall in-hospital MACCE
after DES was similarly lower when compared with BMS (3.5% vs. 7.6%; p<0.001). After adjusting for
all confounding covariables, the DES remained an independent predictor for lower in-hospital mortality
(odds ratio [OR], 0.51;95% confidence interval [CI], 0.40 to0.67; p<0.001). Since groups differed as regards
baseline characteristics and pharmacological treatment we performed a propensity score matching (PSM)
to limit potential biases. Similarly, after the PSM, DES implantation remained independently associated
with reduced risk of in-hospital mortality (adjusted odds ratio [aOR], 0.54; 95% confidence interval [CI],
0.39 to 0.76; p<0.001). Conclusion: In unselected patients from a nationwide, real-world cohort, we
found DES as compared to BMS was associated with lower in-hospital mortality and MACCE. The
identification of optimal treatment strategies of patients with AMI needs further randomized evaluation;
however, our findings suggest potential benefit with DES.
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Abstract
Background: Recently, it has been suggested that the type of stent used in primary 
percutaneous coronary interventions (pPCI) might impact on outcomes of patients with acute 
myocardial infarction (AMI). Indeed, drug-eluting stents (DES) reduce neointimal hyperplasia
when compared to bare-metal stents (BMS); moreover the later generation DES due to its 
biocompatible polymer coatings and stent design allow for greater deliverability, improved 
endothelial healing and therefore less restenosis rate and thrombus generation. However, data 
on the safety and performance of DES in large cohorts of AMI are still limited. 
Aim: To compare the early outcome of DES vs. BMS in acute myocardial infarction patients.
Methods: This was a prospective, multicenter analysis containing patients from 64 hospitals 
in Switzerland with AMI undergoing pPCI between 2005 and 2013. The primary endpoint 
was in-hospital all-cause death, whereas the secondary endpoint included a composite 
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measure of major adverse cardiac and cerebrovascular events (MACCE) of death, 
reinfarction, and cerebrovascular event.
Results: Of 20 464 patients with the primary diagnosis of AMI and enrolled to the AMIS Plus
Registry, 15 026 were referred for pPCI and 13 442 received stent implantation. 10 094 
patients were implanted with DES and 2 260 with BMS. The overall in-hospital mortality was
significantly lower in patients with DES as compared to those with BMS implantation (2.6% 
vs. 7.1%, p<0.001). The overall in-hospital MACCE after DES was similarly lower when 
compared with BMS (3.5% vs. 7.6%; p<0.001). After adjusting for all confounding 
covariables, the DES remained an independent predictor for lower in-hospital mortality (odds 
ratio [OR], 0.51;95% confidence interval [CI], 0.40 to0.67; p<0.001). Since groups differed as
regards baseline characteristics and pharmacological treatment we performed a propensity 
score matching (PSM) to limit potential biases. Similarly,  after the PSM, DES implantation 
remained independently associated with reduced risk of in-hospital mortality (adjusted odds 
ratio [aOR], 0.54; 95% confidence interval [CI], 0.39 to 0.76; p<0.001).
Conclusion: In unselected patients from a nationwide, real-world cohort, we found DES as 
compared to BMS was associated with lower in-hospital mortality and MACCE. The 
identification of optimal treatment strategies of patients with AMI needs further randomized 
evaluation; however, our findings suggest potential benefit with DES.
Key words: acute myocardial infarction, drug-eluting stents, bare-metal stents
Introduction
Primary percutaneous coronary intervention (pPCI) with stent implantation has been 
acknowledged as the most optimal treatment strategy in patients with acute myocardial 
infarction (AMI)1. pPCI with bare metal stent (BMS) implantation has been associated with a 
significant improvement in clinical outcome and therefore has become a standard of practice1.
The introduction of drug eluting stents (DES) has emerged as a rational pPCI alternative in 
this particular setting of AMI2. 
Recently, it has been suggested that the type of stent used in pPCI might impact on 
outcomes of patients with AMI3. Indeed, DES was affirmed to reduce neointimal hyperplasia 
and persistent fibrin deposition when compared to BMS4; moreover the later generation DES 
due to its biocompatible polymer coatings and stent design allow for greater deliverability, 
improved endothelial healing and therefore less restenosis rate and reinfarction5; however, 
concerns have been raised with regard to the safety of DES, particularly in the AMI setting5-7. 
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In recently published COMFORTABLE AMI Trial the comparison of new-generation 
biolimus-eluting stents (BES) and BMS resulted in reduction of a composite of major adverse 
cardiovascular events among patients with STEMI undergoing pPCI8. However, the 
randomized clinical trials (RCTs) did not confirm the benefit of DES as regards the mortality 
rate9. Due to the conflicting reports regarding the hard outcomes after DES versus BMS 
implantation, the most accurate treatment strategy of pPCI during AMI remains nowadays still
the matter of debate.
In this context, we performed a post hoc analysis from the prospective, multicenter 
cohort to investigate whether DES as compared to BMS influence early outcome in the setting
of AMI. The presented all-comer observation addresses the real-world setting and therefore 
reflects the care of patients in routine clinical practice. 
Methods
Study design and population
The AMIS (Acute Myocardial Infarction in Switzerland) Plus project was founded in January 
1997 as a large, nationwide prospective registry of patients admitted with acute coronary 
syndrome (ACS) to 82 hospitals in Switzerland, including ST-segment-elevation myocardial 
infarction (STEMI), non- ST-segment-elevation myocardial infarction (NSTEMI) and 
unstable angina (UA) (Figure 1). The registry is officially supported by the Swiss Societies of 
Cardiology, Internal Medicine and Intensive Care Medicine. The design of the registry has 
been previously described10, 11. All participating centers, ranging from community institutions 
to large tertiary facilities, provide blinded data, being subsequently centralized at the AMIS 
Plus Data Center. All data provided through an internet- or paper-based questionnaires, are 
subsequently checked for plausibility and consistency in the Institute of Social and Preventive
Medicine at the University of Zurich, Switzerland. The registry was approved by the Over-
Regional Ethics Committee for Clinical Studies, the Swiss Board for Data Security and all 
cantonal Ethic Commissions.
Data extraction
The AMIS Plus Central Database collects 230 items including medical history, co-morbidities,
known cardiovascular risk factors (dyslipidemia, arterial hypertension, diabetes, obesity and 
smoking), clinical presentation, out-of-hospital management, early in-hospital management, 
reperfusion therapy, hospital course, diagnostic tests used or planned, length of stay, discharge
medication and discharge destination, immediate drug treatment and discharge medication. 
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The non-cardiovascular co-morbidities were assessed using the Charlson Index12. Patients are 
enrolled in the registry based on their final diagnosis. 
Patients selection
Between January 2005 and March 2013, 20 464 patients with AMI (STEMI and NSTEMI) 
were enrolled to the AMIS Plus Registry, 17 651 underwent any pPCI. Of those, 15 026 
underwent pPCI and 13 442 pPCI with stent implantation. 10 094 patients were implanted 
with DES and 2 260 with BMS. 942 patients were excluded from the final analysis due to 
lacking data regarding the stent type. 146 patients received variable absorbable scaffolds. The 
study flow chart is presented on Figure 2. 
Definitions
The STEMI was defined by characteristic symptoms with ECG changes and cardiac marker 
elevation (creatine kinase MB fraction at least twice the upper limit of normal or troponin I or 
T above individual hospital cut-off levels for MI). All patients required ST-segment elevation 
and/or the new development of left bundle branch block on the initial ECG at presentation. 
NSTEMI was defined as cardiac marker elevation with no ST-elevation in admission ECG. 
Reinfarction was defined as clinical signs or symptoms of ischemia with ECG changes
indicative of new ischemia (new ST-changes or new LBBB) and a re-rise of biomarkers 
following the initial infarction. A cerebrovascular event was defined as any event due to 
ischemic, thrombotic or hemorrhagic disturbances confirmed by a neurologist or imaging 
modality.
Multivessel disease (MVD) was defined as a presence of angiographic stenosis of 
≥50% in at least 2 main epicardial coronary arteries and/or involving the left main (LM) when
a surgical bypass graft was concern. The decision regarding single-vessel PCI (S-PCI) or 
multivessel PCI (M-PCI) attempt and DES or BMS implantation was performed at the 
physician’s discretion.
Study endpoints
The primary endpoint of the study was in-hospital all-cause mortality. Secondary endpoint 
include a composite endpoint of MACCE (major adverse cardiac and cerebrovascular events) 
including death, reinfarction and/or cerebrovascular event.
Statistical analysis
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The results are presented as percentages for categorical variables and analyzed using the non-
parametric Pearson 2 test or Fisher’s exact test as appropriate. Continuous variables are 
expressed as means ± standard deviation (SD) and compared using the Student’s unpaired t-
test for normal distribution and continuous non-normally distributed variables are expressed 
as median and interquartile ranges and analyzed using the Mann-Whitney U test. To examine 
predictors for in-hospital mortality the multivariate logistic regression was used and included 
the following variables: stent type (BMS or DES), multi-vessel revascularization, age, gender,
LM involvement, Killip class>2, Charlson comorbidities weighted index >2 and out-of-
hospital resuscitation. To limit the observational character of the study we performed a 
propensity score matching to create matched DES (n=2137) and BMS (n=2137) cohorts. 
Optimal matching was obtained using a logistic regression model with stent type used as 
dependent variable. Independent variables were age, gender, resuscitation before admission, 
STEMI, Killip class >2, Charlson comorbidity score ≥2 and MVD.
All statistical tests were 2-tailed. P-value of < 0.05 was considered statistical significant. 
SPSS software (version 19, SPSS Inc, Chicago, Illinois, USA) was used for all statistical 
analyses.
Results
Study population and baseline
 Of the included 12 354 patients undergoing the pPCI and stent implantation during AMI 
between 2005 and 2013, we identified 10 094 patients (82%) with DES and 2 260 patients 
(18%) with BMS implantation (Figure 2). Baseline characteristics, stratified by stent use, are 
shown in Table 1. No differences were documented in terms of door-to-balloon time (DES vs. 
BMS: 67 minutes [interquartile range, IQR 25 to 153] vs. 65 minutes [interquartile range, IQR
25 to 135], p=0.22) and the pre-hospital delay (DES vs. BMS: 195 minutes [interquartile 
range, IQR 105 to 490] vs. 180 minutes [interquartile range, IQR 99 to 450], p=0.082). In 
general, rates of BMS implantation were greater among sicker patients with the history of out-
of-hospital reanimation, Killip class III/IV, cerebrovascular disease, renal disease, cancer, and 
Charlson weighted Index ≥2. The DES was more likely used in patients with LM stenosis and 
MVD. In addition, immediate drug therapy with acetylosalicylic acid, glycoprotein IIb/IIIa 
inhibitors, beta-blockers and ACE inhibitors/AT antagonists, and statins were more prevalent 
in patients treated with BMS. In contrast, vasopressors were more frequently used among 
patients receiving DES as compared to BMS No difference was notified in terms of P2Y12 
blockers use between both groups (Table 2). 
5
In-hospital outcomes and predictors of mortality
Overall, in-hospital mortality after DES implantation was lower when compared with BMS 
(2.6% vs. 7.1%, p<0.001) as well as MACCE (3.5% vs. 7.6%, p<0.001, Table 3). 
After adjusting for all different covariables the DES remained a positive independent 
predictor of survival (OR, 0.51;95%CI, 0.40 to 0.67; p<0.001, see Table 4). In multivariable 
regression, STEMI, multivessel disease, left main lesion, age, Charlson weighted Index ≥2, 
out-of-hospital cardiac arrest and Killip III/IV were also identified as predictors of in-hospital 
mortality (Table 4). No differences were notified in the rate of reinfarction and 
cerebrovascular events (Table 3). The additional analysis regarding the cardiogenic shock 
after the pPCI and bleeding rate did not show any differences between both groups receiving 
DES and BMS (Table 3).
Propensity score matching (2137 DES vs. 2137 BMS)
Also after propensity score matching, the significant reduction in mortality rate and overall 
MACCE were notified in patients receiving DES as compared to BMS (3.8% vs. 5.8%, 
p=0.004; 4.8% vs. 6.4%, p=0.033, respectively). DES implantation remained independently 
associated with reduced risk of in-hospital mortality (aOR, 0.54; 95% CI, 0.39 to 0.76; 
p<0.001). 
Discussion
Our results suggest that DES is beneficial as compared to BMS regarding in-hospital 
mortality and overall MACCE. This observational analysis includes a real-world population 
and therefore reflects routine clinical practice.   
DES have been proven more effective than BMS to prevent the need for repeat 
revascularization13-15. The restenosis rate of nearly 20 to 30% within 6 to 9 months after BMS 
implantation has often been called the Achilles’ heel of pPCI16. The introduction of DES 
correlated with reduced angiographic restenosis and ischaemia-driven target vessel 
revascularization (TVR) rates and substantially strengthened the efforts to improve the 
success rate over the last decades17, 18. Restenosis remains the healing response to wire-, 
balloon- and stent-induced injury and comprising neointimal hyperplasia and vessel 
remodeling. However the reduction of restenosis rate relates rather to mid-term follow-up, the
immediate release of drugs (80-90% eluted within 30 days) can rapidly reduce late loss by 
targeting cell cycle division also early after stent implantation19. However, despite the 
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reduction in reintervention rates, no robust clinically relevant differences up to 5-year follow-
up were convincingly identified16. The results abstracted from RCTs revealed no significant 
differences as regards long-term rates of death or myocardial infarction after DES or BMS use
for both off-label and on-label indications17, 20, 21. However, the RCTs were primarily limited 
by population-size. Only the observational studies, with greater numbers of patients presented
DES use as a more optimal treatment strategy as compared to BMS associated with reduced 
death and myocardial infarction20. Importantly, the recently published RCTs suggest that the 
new-generation DES may provide superior clinical outcomes to first-generation DES in 
patients with coronary artery disease and in real-world practice22, 23. The differences were 
driven in part by the in-hospital MI and early in-stent thrombosis24. 
A major matter of debate is DES implantation during the pPCI in patients with AMI16. 
Our analysis based on unselected AMI subset and reflecting the real-world population 
documented the improved adverse outcome measure and all-cause death with similar rate of 
reinfarction. Some prior studies have been similarly in favour of DES (i.e. TYPHOON, 
HORIZONS-AMI, PASEO, and ZEST-AMI), whereas others presented opposite results7, 16, 25, 
26. In the PASEO study, sirolimus- and paclitaxel-eluting stents were documented safe and 
effective as compared to BMS with similar overall mortality27. Mauri et al. in their propensity-
score-matched group documented, that risk-adjusted mortality rates and repeat 
revascularization were lower for DES than for BMS among all patients with AMI including 
both STEMI and NSTEMI, STEMI alone and NSTEMI alone28. The reinfarction was reduced 
after DES implantation as compared to BMS in NSTEMI subset28. On the other hand, the 
PASSION trial have not reveal any benefit after DES implantation as compared to BMS in 
terms of clinical outcomes after one- and five-year observation29, 30. Kaltoft at al. reported 12 
deaths before discharge and four classified as probable stent thrombosis in patients implanted 
with DES and four deaths after BMS implantation including only one possible in-stent 
thrombosis7. The early and late in-stent thrombosis could be caused by i.e. local allergic 
reactions, inflammation, and delayed endothelialization of the first-generation DES31. 
Meanwhile, newly-engineered DES have been developed with the thinner-strut platforms 
made of improved alloys providing increased radial strength and radiopacity5. This may result
in less vascular injury and therefore reduced restenosis and throbogenicity5, 32. The 
EXAMINATION trial comparing everlimus-eluting stents (EES) with BMS in the group of 
STEMI did not reveal any patient-oriented benefit of EES use33 being beneficial as regards the
risk of restenosis and in-stent thrombosis33. The recently published COMFORTABLE trial 
presented that the newly-designed biodegradable polymer biolimus-eluting stents (BES) 
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reduce adverse outcomes as compared to BMS mostly due to a significant reduction in rates 
of reinfarction and reintervention34. Also fewer cases of definite in-stent thrombosis were 
observed in the group of BES when compared with BMS, however the difference was not 
significant34. The use of biodegradable polymers in newly-engineered DES offers the early 
protection against in-stent thrombosis avoiding its very late proinflammatory and 
prothrombotic effect32, 35. Therefore, concerns regarding the late safety issue with DES are 
rather related to early-designed DES8, 36. New DES replaced the early-generation DES in 
clinical practice, and what more, the old-fashioned sirolimus-eluting stents, i.e. CYPHER are 
no longer manufactured5. Nowadays, use of DES in AMI has a class IIA recommendation if 
patients are able to comply with a prolonged regimen of dual antiplatelet therapy16.
Limitations
The major limitation of the presented study is its observational nature with potential for 
selection bias and residual confounding. Thus, patients with AMI who receive DES may be 
less ill than those who receive BMS; our analysis attempted to adjust for these differences to 
the extent that was possible. Second, the study was underpowered to reveal late in-stent 
thrombosis which remains the major limitation of early-generation DES. Third, the use of 
stent type was at the discretion of the operator and no data regarding the use of thrombectomy
are available.  The number of stents was not systematically recorded and therefore an 
additional analysis of cases with mixed stents was not possible. Moreover, our database did 
not allow us to distinguish the particular stent type implanted; therefore, other aspects of the 
stent design (strut size and thickness, stent material, drug or polymer) and its influence on 
outcome remains unknown. The present analysis addresses, however, all consecutive patients 
referred for urgent pPCI due to ACS and reflects the real-world practice. Moreover, since our 
patients were not randomly assigned, we performed a propensity score matching, to limit the 
potential biases.
Conclusions
The use of DES in patients with AMI undergoing pPCI appears to be associated with 
improved mortality and overall in-hospital adverse outcomes as compared to BMS. The 
promising results of the present analysis bear discussion and therefore call for the extended 




AMIS Plus Participants 2005 – 2013 
The authors would like to express their gratitude to the teams of the following hospitals (listed
in alphabetical order with the names of the local principal investigators): Aarau, Kantonsspital
(P Lessing), Affoltern am Albis, Bezirkspital (F Hess), Altdorf, Kantonsspital (R Simon), 
Altstätten, Spital (PJ Hangartner), Baden, Kantonsspital (U Hufschmid), Basel, Kantonsspital 
(P Hunziker/R Jeger), Basel, St. Claraspital (C Grädel/B Hornig), Bern, Beau-Site Klinik (A 
Schönfelder), Bern, Inselspital (S Windecker), Bern, Tiefenauspital (P Loretan), Biel, 
Spitalzentrum (H Schläpfer/C Roethlisberger), Bülach, Spital (G Mang), Burgdorf, 
Regionalspital Emmental (D Ryser), Davos, Spital (G Niedermaier/W Kistler), Dornach, 
Spital (A Droll/T Hongler), Einsiedeln, Regionalspital (S Stäuble), Flawil, Spital (G. 
Freiwald), Frauenfeld, Kantonsspital (HP Schmid), Fribourg, Hôpital cantonal (JC Stauffer/S 
Cook), Frutigen, Spital (K Bietenhard), Genève, Hôpitaux universitaires (PF Keller/M Roffi), 
Grenchen, Spital (B Oertli/R Schönenberger), Herisau, Kantonales Spital (M Schmidli), 
Horgen, See Spital (B Federspiel/D Schröpfer), Interlaken, Spital (EM Weiss), Kreuzlingen, 
Herzzentrum Bodensee (K Weber), La Chaux-de-Fonds, Hôpital (H Zender), Lachen, 
Regionalsspital (C Steffen/I Poepping), Langnau im Emmental, Regionalspital (A Hugi), 
Laufenburg, Gesundheitszentrum Fricktal (J Frei/E Koltai), Lausanne, Centre hospitalier 
universitaire vaudois (JF Iglesias), Lugano, Cardiocentro Ticino (G Pedrazzini), Luzern, 
Kantonsspital (P Erne/F Cuculi), Männedorf, Kreisspital (T Heimes), Mendrisio, Ospedale 
regionale (A Pagnamenta), Meyrin, Hôpital de la Tour (P Urban), Moutier, Hôpital du Jura 
bernois (C Stettler), Münsingen, Regionales Spital Zentrum (F Repond), Münsterlingen, 
Kantonsspital (F Widmer), Muri, Kreisspital für das Freiamt (C. Heimgartner), Nyon, Group. 
Hosp. Ouest lémanique (R Polikar), Olten, Kantonsspital (S Bassetti), Rheinfelden, 
Gesundheitszentrum Fricktal (HU Iselin), Rorschach, Kantonales Spital (M Giger), Samedan, 
Spital Oberengadin (P Egger), Sarnen, Kantonsspital Obwalden (T Kaeslin), Schaffhausen, 
Kantonsspital (R Frey/A Fischer), Schlieren, Spital Limmattal (T Herren/B Caduff), Sion, 
Hôpital du Valais (G Girod), Solothurn, Bürgerspital Solothurn (A Grêt/R Schönenberger/R 
Vogel), Stans, Kantonsspital Nidwalden (B Niggli), St. Gallen, Kantonsspital (H Rickli), 
Sursee, Luzerner Kantonsspital (SI Yoon), Thun, Spital (U Stoller), Uster, Spital (E Bächli), 
Wetzikon, GZO Spital (M Graber/H Vontobel/U Eriksson), Winterthur, Kantonsspital (A 
Haller/T Fischer), Wolhusen, Luzerner Kantonsspital (M Peter), Zofingen, Spital (S Gasser), 
Zollikerberg, Spital (R Fatio), Zug, Kantonsspital (M Vogt/D Ramsay), Zürich, Klinik im 
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Park (O Bertel), Zürich, Universitätsspital Zürich (M Maggiorini), Zürich, Stadtspital Triemli 
(F Eberli), Zürich, Stadtspital Waid (M Fischler/S Christen/S Buchholz).
Table 1. Baseline characteristics of AMI patients, who underwent primary PCI according to 
type of stents {n/N (%)}
Variables BMS DES P value
Number of patients 2260 10094
Gender, male (%) 1716/2260 (75.9) 7857/10094 (77.8) 0.051
Age in years, mean (SD) 65.0 (13.2) 62.3 (12.1) <0.001
Pre-hospital delay (min, median; 
IQR)
180min (99, 450) 195min (105, 490) 0.082
Resuscitation prior admission 220/2259 (9.7) 572/10094 (5.7) <0.001
Killip classes 3/4 239/2235 (10.7) 550/10058 (5.5) <0.001
STEMI 1736/2260 (76.8) 7155/10094 (70.9) <0.001
Family history 537/1796 (29.9) 3081/8730 (35.3) <0.001
Current smoker 810/1857 (43.6) 3861/8481 (45.5) 0.14
Dyslipidemia 983/1929 (51.0) 4644/8921 (52.1) 0.39
Hypertension 1179/2084 (56.6) 5280/9511 (55.5) 0.38
Obesity ( BMI>30)  366/1808 (20.2) 1697/7995 (21.1) 0.37
Diabetes 328/2104 (15.6) 1570/9650 (16.3) 0.45
Coronary artery disease 525/2205 (23.8) 2883/9968 (28.9) <0.001
Past history of AMI 202/2166 (9.3) 1260/9862 (12.8) <0.001
Heart failure 34/2164 (1.6) 149/9856 (1.5) 0.85
Cerebrovascular disease 105/2164 (4.9) 309/9856 (3.1) <0.001
Renal disease (moderate to severe) 102/2164 (4.7) 338/9856 (3.4) 0.005
Cancer diseases 127/2164 (5.9) 387/9856 (3.9) <0.001
Charlson Score ≥2 337/2164 (17.4) 1438/9856 (14.6) 0.001
Left main 67/2253 (3.0) 479/10055 (4.8) <0.001
Multivessel disease 1235/2255 (54.8) 5921/10057 (58.9) <0.001
Door-to-balloon time (min, median; 
IQR)
65min (25, 135) 67min (25, 153) 0.22
Data are presented as n (%) or mean±SD or median with inter-quartile range;
AMI=acute myocardial infarction; BMI=body mass index; BMS=bare-metal stent; DES=drug-
eluting stent; IQR= inter-quartile range; STEMI=ST-segment elevation myocardial infarction; 
Table 2. Immediate drug therapy {n/N (%)}
Variables BMS DES P value
Number of patients 2260 10094
ASS 2191/2253 (97.2) 9899/10074 (98.3) 0.002
P2Y12 blocker* 2151/2251 (95.6) 9638/10067 (95.7) 0.69
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GP IIb/IIIa 696/2204 (31.6) 3437/9947 (34.6) 0.008
Vasopressors 321/2201 (14.6) 828/9905 (8.4) 0.001
Beta blocker 1176/2218 (53.0) 6385/10003 (63.8) 0.001
ACEI/AT 1177/2221 (53.0) 6089/10021 (60.8) <0.001
Statin 1700/2232 (76.2) 8264/10028 (82.4) <0.001
Data are presented as n (%); ASS= acetylosalicylic acid; ACEI= angiotensin-
converting-enzyme inhibitor; AT= angiotensin II receptor antagonists; 
BMS=bare-metal stent; DES=drug-eluting stent; *clopidogrel, or prasugrel or 
ticagrelor; 
Table 3. In-hospital complications and outcome of AMI, who underwent primary 
PCI according to type of stents {n/N (%)}
BMS DES P value
Number of patients 2260 10094
Complication 
Cardiogenic shock 110/2260 (4.9) 280/10063 (2.8) <0.001
Cerebrovasular events 9/2260 (0.4) 54/10063 (0.5) 0.51
Bleeding 81/2260 (3.6) 311/10063 (3.1) 0.23
Re-infarction 13/2260 (0.6) 79/10063 (0.8) 0.34
Mortality 160/2260 (7.1) 263/10094 (2.6) <0.001
MACE* 165/2157 (7.6) 321/9232 (3.5) <0.001
Data are presented as n (%); BMS=bare-metal stent; DES=drug-eluting stent; 
*MACE=major adverse cardiac and cerebrovascular event 
Table 4. Independent predictor of in-hospital mortality
Variables OR 95%CI P value
DES vs. BMS 0.52 0.40–0.68 <0.001
STEMI 1.43 1.06-1.91 0.018
Multivessel disease 1.39 1.06-1.81 0.017
Left main 1.89 1.27-2.81 0.002
Female gender 1.00 0.75-1.32 0.99
Age (per additional year) 1.05 1.04-1.06 <0.001
Charlson weighted Index =>2 2.23 1.71-2.92 <0.001
Resuscitation prior admission 5.91 4.37-7.99 <0.001
Killip class >2 11.6 8.84-15.1 <0.001
BMS=bare-metal stent; DES=drug-eluting stent; OR=odds ratio; STEMI=ST-
segment elevation myocardial infarction;
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Figure 1. All hospitals who have participated in AMIS project (red color - current 
participating hospitals)
Figure 2. Study flow chart
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